B. You

An Analysis Regarding the Prognostic Significance of MAVS and Its Underlying Biological Mechanism in Ovarian Cancer

Xiaodong Cheng, X. Tu, Feifei Song, 2021, Frontiers in Cell and Developmental Biology.

Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germlineBRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

A. Italiano, S. Domchek, S. Im, 2019, Poster Discussion Abstracts.

529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer

Y. Drew, R. Plummer, P. Roxburgh, 2022, Annals of Oncology.

Progestin-Primed Ovarian Stimulation Versus Mild Stimulation Protocol in Advanced Age Women With Diminished Ovarian Reserve Undergoing Their First In Vitro Fertilization Cycle: A Retrospective Cohort Study

Runju Zhang, B. You, Miaomiao Jing, 2022, Frontiers in Endocrinology.

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

T. Park-Simon, I. Vergote, I. Ray-Coquard, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .